Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells

Cancer Letters

Volumn 367, Issue 1, 2015, Pages 69-75

  Munoz, Jessian L ^a,b   Walker, Nykia D ^b   Scotto, Kathleen W ^c   Rameshwar, Pranela ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b University of Medicine and Dentistry of New Jersey   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Chemoresistance; Glioblastoma; MDR1; P gp; Temozolomide

Indexed keywords

CALCEIN; CASPASE 3; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TEMOZOLOMIDE; ABCB1 PROTEIN, HUMAN; ALKYLATING AGENT; CASP3 PROTEIN, HUMAN; DACARBAZINE; FLUORESCEIN DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER SURVIVAL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; BRAIN TUMOR; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HAMSTER; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BINDING, COMPETITIVE; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CRICETINAE; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLUORESCEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; P-GLYCOPROTEINS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UP-REGULATION;

EID: 84939264440     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.07.013     Document Type: Article

References (25)

1. Gros P., Croop J., Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986, 47:371-380.
2. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
3. Li Y., Yuan H., Yang K., Xu W., Tang W., Li X. The structure and functions of P-glycoprotein. Curr. Med. Chem 2010, 17:786-800.
4. Chen C.J., Clark D., Ueda K., Pastan I., Gottesman M.M., Roninson I.B. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem 1990, 265:506-514.
5. Holland E.C. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6242-6244.
6. Friedman H.S., Kerby T., Calvert H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res 2000, 6:2285-2297.
7. Marchesi F., Turriziani M., Tortorelli G., Avvisati G., Torino F., De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharm. Res 2007, 56:275-287.
8. He H., Ni J., Huang J. Molecular mechanisms of chemoresistance in osteosarcoma. Oncol. Lett 2014, 7:1352-1362.
9. Decleves X., Fajac A., Lehmann-Che J., Tardy M., Mercier C., Hurbain I., et al. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int. J. Cancer 2002, 98:173-180.
10. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem 1990, 38:1277-1287.
11. Demeule M., Shedid D., Beaulieu E., Del Maestro R.F., Moghrabi A., Ghosn P.B., et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int. J. Cancer 2001, 93:62-66.
12. Munoz J.L., Rodriguez-Cruz V., Ramkissoon S.H., Ligon K.L., Greco S.J., Rameshwar P. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget 2015, 6:1190-1201.
13. Munoz J.L., Rodriguez-Cruz V., Rameshwar P. High expression of MIR-9 in CD133+ glioblastoma cells in chemoresistance to temozolomide. J. Cancer Stem Cell Res 2015, 3. In press.
14. Munoz J.L., Rodriguez-Cruz V., Greco S.J., Nagula V., Scotto K.W., Rameshwar P. Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. Mol. Cancer Ther 2014, 13:2399-2411.
15. Ince T.A., Scotto K.W. Stable transfection of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1. Cancer Res 1996, 56:2021-2024.
16. Bikadi Z., Hazai I., Malik D., Jemnitz K., Veres Z., Hari P., et al. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. PLoS ONE 2011, 6:e22815.
17. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
18. Kars M.D., Iseri O.D., Gunduz U., Ural A.U., Arpaci F., Molnar J. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 2006, 26:4559-4568.
19. Tiberghien F., Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 1996, 7:568-578.
20. Zhang Y., Bachmeier C., Miller D.W. In vitro and in vivo models for assessing drug efflux transporter activity. Adv. Drug Deliv. Rev 2003, 55:31-51.
21. Sarkaria J.N., Kitange G.J., James C.D., Plummer R., Calvert H., Weller M., et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res 2008, 14:2900-2908.
22. Muni R., Minniti G., Lanzetta G., Caporello P., Frati A., Enrici M.M., et al. Short-term radiotherapy followed by adjuvant chemotherapy in poor-prognosis patients with glioblastoma. Tumori 2010, 96:60-64.
23. Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev 2002, 54:1295-1310.
24. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther 2004, 75:13-33.
25. Schaich M., Kestel L., Pfirrmann M., Robel K., Illmer T., Kramer M., et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann. Oncol 2009, 20:175-181.